Encompass Health Corporation EHC
123.47
1.46
1.20%
as of 25 Sep
- Market cap
- $12.0B
- P/E
- 19.9×
Follow EHC
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
23.57 | 18.85 | 15.91 | 16.25 |
P/S ratio |
2.20 | 1.80 | 1.58 | 1.61 | |
P/FCF ratio |
34.22 | 26.04 | 22.07 | 26.02 | |
P/Operating CF |
47.14 | 30.83 | 30.65 | 35.34 | |
P/B ratio |
4.08 | 3.32 | 2.90 | 2.93 | |
Price to Tangible BV |
8.31 | 6.70 | 5.68 | 5.63 | |
EV/Sales |
2.61 | 2.20 | 1.98 | 2.01 | |
EV/EBITDA |
11.35 | 9.39 | 8.38 | 8.50 | |
EV/Operating CF |
13.63 | 11.10 | 10.00 | 10.30 | |
EV/FCF |
40.50 | 31.87 | 27.61 | 32.54 | |
Quick Ratio |
0.92 | 0.86 | 0.96 | 0.94 | |
Current Ratio |
1.14 | 1.08 | 1.17 | 1.19 | |
Net Debt/EBITDA |
7.18 | 6.29 | 6.20 | 6.66 | |
Debt/Assets |
35.44% | 35.13% | 35.19% | 35.32% | |
Debt/Equity |
0.78 | 0.77 | 0.78 | 0.77 | |
Asset Turnover |
0.87 | 0.87 | 0.87 | 0.87 | |
Operating CF/Net income |
2.14 | 2.36 | 1.61 | 1.84 | |
Capex/Depreciation |
(2.27) | (2.39) | (1.86) | (2.44) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
61.29% | 60.47% | 59.28% | 59.41% | |
Intangible Assets out of Total Assets |
0.23 | 0.23 | 0.22 | 0.22 | |
Share Based Compensation of Revenue |
0.97% | 1.19% | 0.72% | 0.86% | |
Graham Net Nets |
(0.22) | (0.28) | (0.31) | (0.30) | |
Graham Number |
61.48 | 63.68 | 67.55 | 69.43 | |
Earnings Yield |
4.24% | 5.30% | 6.29% | 6.15% | |
Free Cash Flow Yield |
2.92% | 3.84% | 4.53% | 3.84% | |
Revenue per Share |
14.70 | 15.37 | 15.99 | 16.17 | |
Operating CF per Share |
2.69 | 3.44 | 3.16 | 2.86 | |
Capex per Share |
(1.86) | (2.28) | (1.64) | (2.23) | |
Free Cash Flow per Share |
0.83 | 1.16 | 1.52 | 0.63 | |
Cash per Share |
0.93 | 1.02 | 1.65 | 1.35 | |
Shareholders Equity per Share |
31.16 | 32.01 | 33.35 | 34.45 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
31.16 | 32.01 | 33.35 | 34.45 | |
Free Cash Flow |
83.70 | 116.70 | 150.70 | 62.30 | |
Working Capital |
107.80 | 69.50 | 152.30 | 167.60 | |
Capital Expenditures |
(187.10) | (229.30) | (162.40) | (220.30) | |
Net Current Asset Value |
(2,864.00) | (2,966.30) | (2,975.70) | (3,013.30) | |
EV/EBIT |
15.08 | 12.40 | 11.04 | 11.21 | |
Capex to Sales |
0.13 | 0.15 | 0.10 | 0.14 | |
Net Profit Margin |
8.56% | 9.48% | 12.26% | 9.61% | |
Price to Operating Income |
12.75 | 10.13 | 8.82 | 8.97 | |
| Other line items | |||||
Average Receivables |
593.60 | 609.00 | 649.70 | 649.90 | |
Average Payables |
154.35 | 174.60 | 181.55 | 198.05 | |
Average Assets |
6,662.05 | 6,812.20 | 6,977.25 | 7,121.60 | |
Average Common Equity |
2,900.50 | 3,005.10 | 3,094.95 | 3,218.15 |
Columns are period end dates